Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: jopawa who wrote (835)	1/5/1999 9:03:00 PM
From: Anthony Wong	Read Replies (4) \| Respond to of 2539

Salomon Smith Barney Conference Call Summary, copied from Yahoo MTC thread: messages.yahoo.com@m2.yahoo.com "07:52am EST 5-Jan-99 Salomon Smith Barney (HEUER/WILBUR (212) 816-0232) MTC PF --SUMMARY:--Monsanto--Chemicals: Major * Celebrex will be launched in US in late January, detailing begins Feb 22. * Celebrex priced at $2.42/day -- a slight discount to top NSAID brands priced at $2.40-$2.85/day. * Searle + PFE reps supporting Celebrex could number 3,000-4,000; Searle advertised a record-breaking volume of details to physicians on Celebrex. * Celebrex ramp-up could be awesome due to superior GI profile, aggressive price, unprecedented sales rep support, many foreign launches; only "downer" is heavy sampling that begins Jan 25. Our 1999E sales $800 MM. * Celebrex RA indication is worth more than Vioxx pain indication, because RA doses are larger and are taken longer vs doses for pain. * Searle could "punt" on pain claim for Celebrex, but is conducting a major "outcomes" trial to secure removal of GI warning label."